Research priorities in biomarkers and surrogate end-points

British Journal of Clinical Pharmacology

Volumn 73, Issue 6, 2012, Pages 900-907

  Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; HYDRALAZINE; ISOSORBIDE;

ANTIHYPERTENSIVE THERAPY; ASTHMA; CLINICAL PHARMACOLOGY; DISEASE MARKER; EXERCISE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; NOTE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; REPRODUCIBILITY; RESEARCH PRIORITY; SEIZURE; SENSITIVITY AND SPECIFICITY; SMOKING;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN;

EID: 84860695212     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04234.x     Document Type: Note

References (24)

1. Kuru T, Lynch JP III. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20: 623-51.
2. Bourdain A. Typhoid Mary: An Urban Historical. New York: Bloomsbury, 2001.
3. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 297-302.
4. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 1989; 8: 415-25.
5. NIH Definitions Working Group. Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. In: Biomarkers and Surrogate Endpoints, ed. Downing GJ. Amsterdam: Elsevier, 2000; 1-9.
6. Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J 2002; 19: 202-5 [erratum: 376].
7. Thomas SHL. An agenda for UK clinical pharmacology: Developing and delivering clinical toxicology in the UK National Health Service. Br J Clin Pharmacol 2012; 73: 878-83.
8. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
9. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005; 59: 491-4.
10. Wald NJ, Hacksaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999; 319: 1562-5.
11. Gargano G, Correale M, Abbate I, Falco G, De Frenza N, Lorusso V, De Lena M, De Leonardis A. The role of tumour markers in ovarian cancer. Clin Exp Obstet Gynecol 1990; 17: 23-9.
12. Jortani SA, Prabhu SD, Valdes R Jr. Strategies for developing biomarkers of heart failure. Clin Chem 2004; 50: 265-78.
13. The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
14. Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med 2010; 103: 433-41.
15. Cohn J. Lessons from V-HeFT: questions for V-HeFT11 and the future therapy of heart failure. Herz 1991; 16: 267-71.
16. Reynolds DJ, Aronson JK. ABC of monitoring drug therapy. Cyclosporin. BMJ 1992; 305: 1491-4.
17. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 2004; 58: S867-71.
18. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 220-6.
19. Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1385-91.
20. Ford L, Prout C, Gaffney D, Berg J. Whose TPMT activity is it anyway? Ann Clin Biochem 2004; 41 (Pt 6): 498-500.
21. Higgs CMB, Laszlo G. Influence of treatment with beclomethasone, cromoglycate and theophylline on perception of bronchoconstriction in patients with bronchial asthma. Clin Sci 1996; 90: 227-34.
22. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-40.
23. Institute of Medicine of the National Academies. Evaluation of biomarkers and surrogate endpoints in chronic disease. 2010. Available at (last accessed 18 January 2012).
24. Aronson JK. Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In: Evidence-Based Medical Monitoring: From Principles to Practice, eds Glasziou P, Irwig L, Aronson JK. Oxford: Wiley-Blackwell Ltd, 2008; 48-62.